Monitoring Test Helps Guide Inflammatory Bowel Disease Management
|
By LabMedica International staff writers Posted on 31 Jul 2012 |
|
A new generation test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients who use infliximab.
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Immunology News
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Urine-Based Assay Predicts Severe Dengue Risk Early
Dengue is among the most widespread mosquito-borne infections, yet early risk stratification can be difficult when symptoms overlap with other febrile illnesses. Only about 2% to 5% of patients develop... Read more
CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis
Multiple sclerosis affects more than 2.9 million people worldwide and requires ongoing evaluation of disease activity to guide care. Routine monitoring often depends on magnetic resonance imaging (MRI),... Read more
Ultrasensitive Assay Tracks Resistance Mutations MRD Monitoring
Ultrasensitive circulating tumor DNA assessment is being applied to predict and track response to immunotherapy and to detect relapse across multiple solid tumors. Monitoring resistance mutations such... Read more
Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition whose incidence is rising in industrialized and newly industrialized countries, with prevalence in early‑industrialized... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
Microbiology
view channel
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
Pathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
AI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
Clinicians often struggle to distinguish bacterial from viral infections at first presentation because symptoms overlap and definitive culture or molecular results can take hours or days.... Read more
